What is the appropriate management for a 1.6 cm branch‑duct intraductal papillary mucinous neoplasm (IPMN) with a borderline CA 19‑9 level of 37 U/mL?

Management of 1.6 cm Branch-Duct IPMN with CA 19-9 at 37 U/mL

This 1.6 cm branch-duct IPMN with borderline CA 19-9 elevation (37 U/mL) should undergo enhanced surveillance with MRI/MRCP and consideration for EUS-FNA, rather than immediate surgery, but requires closer monitoring than standard low-risk lesions. 1

Risk Stratification

Your patient presents with one relative indication for surgery according to European guidelines:

• CA 19-9 at exactly 37 U/mL is at the threshold cutoff (>37 U/mL is considered elevated) 1
• The cyst size of 1.6 cm is below the 40 mm threshold that would constitute another relative indication 1
• No absolute indications are present (no jaundice, solid mass, mural nodules ≥5 mm, or main pancreatic duct ≥10 mm) 1

Critical context: CA 19-9 >37 U/mL has a positive predictive value of 74% and accuracy of 81.7% for identifying invasive IPMN, and is associated with both invasive carcinoma and worse overall survival 1, 2. However, your patient is technically at the threshold, not clearly above it.

Recommended Management Algorithm

Immediate Steps

1. Obtain high-quality MRI with MRCP to evaluate for additional worrisome features 1:

   • Assess for mural nodules (even <5 mm, which are relative indications) 1
   • Measure main pancreatic duct diameter precisely (5-9.9 mm is a relative indication) 1, 3
   • Look for enhancing solid components
   • Evaluate cyst morphology and any synchronous lesions

2. Consider EUS-FNA if any additional worrisome features are identified 1:

   • The combination of borderline CA 19-9 plus any other worrisome feature increases malignancy risk substantially 1
   • EUS can better characterize mural nodules and obtain cytology 1

If No Additional Worrisome Features Present

Enhanced surveillance protocol (not standard low-risk surveillance):

• First year: Imaging every 3-6 months 4

  • Approximately 10% of branch-duct IPMNs develop new malignant stigmata requiring surgery within the first year 4
  • The borderline CA 19-9 justifies closer initial monitoring

• After first year if stable: Transition to imaging every 6-12 months 1

  • Continue for minimum 5 years 1
  • Growth rate ≥5 mm/year is a relative indication for surgery 1

• Repeat CA 19-9 at each surveillance interval 2

  • Rising CA 19-9 levels warrant surgical evaluation even without imaging changes 2

Surgical Referral Triggers During Surveillance

Refer for surgical evaluation if any of the following develop:

Absolute indications 1:

• Main pancreatic duct ≥10 mm
• Enhancing mural nodule ≥5 mm
• Jaundice
• Positive cytology for malignancy/high-grade dysplasia

Multiple relative indications (presence of 2+ warrants strong surgical consideration) 1:

• CA 19-9 clearly rising above 37 U/mL
• Growth rate ≥5 mm/year
• Cyst reaches 40 mm
• Main pancreatic duct 5-9.9 mm
• New-onset diabetes or acute pancreatitis
• Mural nodule <5 mm

Key Caveats

The CA 19-9 interpretation requires caution:

• Ensure no concurrent biliary obstruction or jaundice, which can falsely elevate CA 19-9 1
• Approximately 10% of the population are Lewis antigen-negative and cannot produce CA 19-9 (always low regardless of malignancy)
• Benign conditions (cholangitis, pancreatitis) can elevate CA 19-9

Patient factors matter for surgical decisions:

• Age and comorbidities influence operative risk 1, 5
• Even after resection of IPMN, lifelong surveillance remains necessary 1
• The 5-year disease-free survival after resection of IPMN is 96%, but surgery carries significant morbidity 1

Do not rely on size alone: Even small IPMNs can harbor malignancy, particularly when other risk factors are present 1, 6. The combination of features is more predictive than any single parameter 1.